Hansa Biopharma AB (HNSA.ST)

Nasdaq Stockholm · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), Hansa Biopharma AB reported revenue of SEK 171.3M and net income of −SEK 807.2M. Annual financial statements are available for fiscal years 2020 to 2024, taken from the company's ESEF annual reports (IFRS).

Open interactive financials →

Key financials

SEK	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31	FY2020 2020-12-31
Income statement
Revenue	SEK 171.3M	SEK 134.1M	SEK 154.5M	SEK 33.9M	SEK 6.1M
Gross profit	SEK 87.8M	SEK 71.0M	SEK 116.0M	SEK 18.5M	SEK 5.1M
Operating income	−SEK 637.9M	−SEK 788.5M	−SEK 588.6M	−SEK 547.0M	−SEK 422.8M
Net income	−SEK 807.2M	−SEK 831.7M	−SEK 611.1M	−SEK 548.3M	−SEK 420.9M
Diluted EPS	−SEK 12.85	−SEK 15.83	−SEK 13.60	−SEK 12.33	−SEK 9.98
Cash flow
Operating cash flow	−SEK 674.9M	−SEK 755.7M	−SEK 502.7M	−SEK 481.2M	−SEK 290.3M
Capital expenditure	SEK 116.0K	SEK 284.0K	SEK 3.3M	SEK 2.4M	SEK 294.0K
Free cash flow	−SEK 675.0M	−SEK 755.9M	−SEK 506.1M	−SEK 483.6M	−SEK 290.6M
Balance sheet
Cash and equivalents	SEK 405.3M	SEK 732.1M	SEK 1.50B	SEK 651.3M	SEK 1.14B
Total assets	SEK 800.6M	SEK 1.02B	SEK 1.69B	SEK 1.01B	SEK 1.43B
Total liabilities	–	–	SEK 1.08B	SEK 255.2M	SEK 192.4M
Total debt	SEK 1.06B	SEK 844.9M	SEK 762.6M	SEK 0	–
Shareholders' equity	−SEK 589.8M	−SEK 167.9M	SEK 602.9M	SEK 757.6M	SEK 1.24B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full HNSA.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open HNSA.ST financials →